The issuance of new patents in key markets like Europe and China not only protects ENDRA Life Sciences' innovations but also potentially opens up new revenue streams through licensing or direct product sales. This development is likely to be viewed positively by investors, as it represents both a strategic advancement in the company's intellectual property strategy and a potential for future growth.